# US 2025/0205356 A1 · Polymer-drug conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205356 A1
- Document ID: US20250205356A1
- Status: Published application
- Kind: A1
- Application number: 18/848,135
- Filed: 2023-03-20
- Published: 2025-06-26
- Earliest claimed: 2022-03-21
- Assignees: Primelink Biotherapeutics (Shenzhen) Co., Ltd
- Applicants: Primelink Biotherapeutics (Shenzhen) Co., Ltd
- Inventors: Mao YIN; Xianhua YI; Yingdong LU; Xiaohe SHI; Ling XIN; Guangchao ZHANG; Jiani YU; Yu SHEN
- Web page: https://patentgrep.com/patent/US20250205356A1

## CPC

- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- C07D 207/448: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/595: {Polyamides, e.g. nylon (polyamino acids A61K47/62)}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6883: {Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy}
- C07D 405/14: containing three or more hetero rings
- C07D 491/147: the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
- C07D 491/22: in which the condensed system contains four or more hetero rings
- C08G 65/48: Polymers modified by chemical after-treatment
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS

## Abstract

A polymeric scaffold useful for conjugating with a targeting moiety can form a targeting moiety-polymer-drug conjugate. A targeting moiety-polymer-drug conjugate is prepared from the polymeric scaffold. Compositions comprise the conjugates. Methods of their preparation and methods of treating various disorders with the conjugates or their compositions.

## Claims

### Claim 1

A polymeric scaffold of Formula (I) useful to conjugate with a targeting moiety:
wherein:
the polymeric scaffold comprises linear polyglycerol;
L is a linking moiety comprising a functional group Wp that is capable of forming a covalent bond with the targeting moiety;
Ma is a stretcher connecting L to —NH— moiety;
each G1 is independently a functional group connecting Lp to the linear polyglycerol;
each Lp is independently a drug release mechanism between a therapeutic agent moiety D and G1;
each D is independently a therapeutic agent moiety;
each G2 is independently a functional group capable of converting into a charged state;
n is an integer from 0 to 1000;
m is an integer from 0 to 1000;
p is an integer from 0 to 1000; and
q is an integer from 0 to 1000.

### Claim 2 (depends on 1)

The polymeric scaffold of claim 1, wherein Wp is capable of reacting with a functional group on the targeting moiety with a click reaction.

### Claim 3 (depends on 2)

The polymeric scaffold of claim 2, wherein Wp is selected from the group consisting of:

### Claim 4 (depends on 1)

The polymeric scaffold of claim 1, wherein Wp is capable of reacting with amino acids on the targeting moiety.

### Claim 5 (depends on 4)

The polymeric scaffold of claim 4, wherein the amino acids are natural amino acids, non-natural amino acids or combination thereof.

### Claim 6 (depends on 5)

The polymeric scaffold of claim 5, wherein the natural amino acid comprises cysteine, lysine, tyrosine, aspartic acid and glutamic acid.

### Claim 7 (depends on 4)

The polymeric scaffold of claim 4, wherein Wp is capable of reacting with one or more cysteines on the targeting moiety.

### Claim 8 (depends on 7)

The polymeric scaffold of claim 7, wherein Wp is selected from the group
wherein R1 is a sulfur protecting group, each R2 is independently a leaving group.

### Claim 9 (depends on 8)

The polymeric scaffold of claim 8, wherein each R2 is independently selected from halo or R2aC(O)O—, in which R2a is hydrogen, an aliphatic, heteroaliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

### Claim 10 (depends on 4)

The polymeric scaffold of claim 4, wherein Wp is capable of reacting with one or more lysines on the targeting moiety, in which each Wp is independently selected from the group consisting of:

### Claim 11 (depends on 4)

The polymeric scaffold of claim 4, wherein Wp is capable of reacting with one or more non-natural amino acids on the targeting moiety.

### Claim 12 (depends on 11)

The polymeric scaffold of claim 11, wherein Wp is selected from:

### Claim 13 (depends on 1)

The polymeric scaffold of claim 1, wherein Ma is selected from the group
wherein * is the site covalently attached to L, ** is the site covalently attached to —NH— moiety,
R3 is C1-10 alkyl, C1-10 heteroalkyl, C3-8 cycloalkyl, —O—(C1-8 alkyl)-, aryl, —C1-10 alkyl-aryl-, -aryl-C1-10 alkyl-, —C1-10 alkyl-(C3-8 cycloalkyl)-, —(C3-8 cycloalkyl-C1-10 alkyl)-, 4- to 14-membered heterocycloalkyl, —C1-10 alkyl-(4- to 14-membered heterocycloalkyl)-, -(4- to 14-membered heterocycloalkyl)-C1-10 alkyl-, —C1-10 alkyl-C(═O)—, —C1-10 heteroalkyl-C(═O)—, —C3-8 cycloalkyl-C(═O)—, —O—(C1-8 alkyl)-C(═O)—, -aryl-C(═O)—, —C1-10 alkyl-aryl-C(═O)—, -aryl-C1-10 alkyl-C(═O)—, —C1-10 alkyl-(C3-8 cycloalkyl)-C(═O)—, —(C3-8 cycloalkyl)-C1-10 alkyl-C(═O)—, -4- to 14-membered heterocycloalkyl-C═(O)—, —C1-10 alkyl-(4- to 14-membered heterocycloalkyl)-C(═O)—, -(4- to 14-membered heterocycloalkyl)-C1-10 alkyl-C(═O)—, —C1-10 alkyl-NH—, —C1-10 heteroalkyl-NH—, —C3-8 cycloalkyl-NH—, —O—(C1-8 alkyl)-NH—, -aryl-NH—, —C1-10 alkyl-aryl-NH—, -aryl-C1-10 alkyl-NH—, —C1-10 alkyl-(C3-8 cycloalkyl)-NH—, —(C3-8 cycloalkyl)-C1-10 alkyl-NH—, -4- to 14-membered heterocycloalkyl-NH—, —C1-10 alkyl-(4- to 14-membered heterocycloalkyl)-NH—, -(4- to 14-membered heterocycloalkyl)-C1-10 alkyl-NH—, —C1-10 alkyl-S—, —C1-10 heteroalkyl-S—, —C3-8 cycloalkyl-S—, —O—C1-8 alkyl-S—, -aryl-S—, —C1-10 alkyl-aryl-S—, -aryl-C1-10 alkyl-S—, —C1-10 alkyl-(C3-8 cycloalkyl)-S—, —(C3-8 cycloalkyl)-C1-10 alkyl-S—, -4- to 14-membered heterocycloalkyl-S—, —C1-10 alkyl-(4- to 14-membered heterocycloalkyl)-S—, or -(4- to 14-membered heterocycloalkyl)-C1-10 alkyl-S—;
each R4 independently is hydrogen, C1-6 alkyl, C6-10 aryl, C3-8 cycloalkyl, —COOH or —COO—C1-6 alkyl;
R5 is —C(O)—NR5a or —NR5a—C(O)—;
R5a is hydrogen, C1-6 alkyl, C6-10 aryl, C3-8 cycloalkyl, —COOH or —COO—C1-6 alkyl;
R6 is a bond or —NR6a—(CR6bR6c)—C(O)—;
R6a is hydrogen, C1-6 alkyl, C6-10 aryl, C3-8 cycloalkyl, —COOH or —COO—C1-6 alkyl;
each R6b and R6c independently is hydrogen, C1-6 alkyl, C6-10 aryl, hydroxylated C6-10 aryl, polyhydroxylated C6-10 aryl, 5- to 12-membered heterocycloalkyl, C3-8 cycloalkyl, hydroxylated C3-8 cycloalkyl, polyhydroxylated C3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
each n1 independently is an integer from 0 to 6;
n2 is an integer from 0 to 8;
each n3 independently is an integer from 1 to 6; and
n4 is an integer from 1 to 4.

### Claim 14 (depends on 13)

The polymeric scaffold of claim 13, wherein Ma is selected from the group consisting of:

### Claim 15 (depends on 1)

The polymeric scaffold of claim 1, wherein G1 is selected from the group consisting of:
wherein * is the site covalently attached to Lp, each R7 is independently selected from a direct bond, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, and R7a is selected from hydrogen, an aliphatic, heteroaliphatic, cycloalkyl, or heterocycloalkyl moiety.

### Claim 16 (depends on 1)

The polymeric scaffold of claim 1, wherein G1 is selected from the group consisting of:
wherein R7 is selected from hydrogen, an aliphatic, heteroaliphatic, cycloalkyl, or heterocycloalkyl moiety.

### Claim 17 (depends on 1)

The polymeric scaffold of claim 1, wherein each Lp independently comprises a labile structure.

### Claim 18 (depends on 17)

The polymeric scaffold of claim 17, wherein the labile structure is selected from hydrolytically labile structures or enzymatic labile structures.

### Claim 19 (depends on 18)

The polymeric scaffold of claim 18, wherein the hydrolytically labile structure is selected from the group consisting of:
wherein * is the site covalently attached to G1, ** is the site covalently attached to D, R8 is selected from hydrogen, alky or aryl, R9 is selected from aliphatic, heteroaliphatic, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.

### Claim 20 (depends on 18)

The polymeric scaffold of claim 18, wherein the hydrolytically labile structure is selected from the group consisting of:
wherein * is the site covalently attached to G1, ** is the site covalently attached to D, R8 is selected from hydrogen, alky or aryl, R9 is selected from aliphatic, heteroaliphatic, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.

### Claim 21 (depends on 20)

The polymeric scaffold of claim 20, wherein G1 is
wherein * is the site covalently attached to Lp, R7 is alkyl.

### Claim 22 (depends on 21)

The polymeric scaffold of claim 21, wherein -G1-Lp-D is

### Claim 23 (depends on 17)

The polymeric scaffold of claim 17, wherein the enzymatic labile structure is liable to enzymes selected from Cathepsin B, phosphatase, sulfatase, or glucuronidase.

### Claim 24 (depends on 19)

The polymeric scaffold of claim 19, wherein the enzymatic labile structure is liable to cathepsin B and is selected from —Z— or
wherein Z is a substrate for cathepsin B comprising 2 to 4 amino acids.

### Claim 25 (depends on 24)

The polymeric scaffold of claim 24, wherein G1 is
wherein * is the site covalently attached to Lp, R7 is alkyl.

### Claim 26 (depends on 24)

The polymeric scaffold of claim 24, wherein -G1-Lp-D is

### Claim 27 (depends on 23)

The polymeric scaffold of claim 23, wherein the enzymatic labile structure is liable to glucuronidase and is
wherein * is the site covalently attached to G1, ** is the site covalently attached to D.

### Claim 28 (depends on 27)

The polymeric scaffold of claim 27, wherein G1 is
wherein R7 is selected from hydrogen, aliphatic, heteroaliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

### Claim 29 (depends on 27)

The polymeric scaffold of claim 27, wherein G1 is
wherein * is the site covalently attached to Lp, R7 is alkyl.

### Claim 30 (depends on 27)

The polymeric scaffold of claim 27, wherein -Lp-D is selected from:

### Claim 31 (depends on 27)

The polymeric scaffold of claim 27, wherein -G1-Lp-D is selected from:

### Claim 32 (depends on 23)

The polymeric scaffold of claim 23, wherein the enzymatic labile structure is liable to phosphatase and is selected from
wherein * is the site covalently attached to G1, ** is the site covalently attached to D, each of R10 and R11 is independently hydrogen, an aliphatic, heteroaliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

### Claim 33 (depends on 32)

The polymeric scaffold of claim 32, wherein G1 is

### Claim 34 (depends on 33)

The polymeric scaffold of claim 33 wherein -G1-Lp-D is selected from the group consisting of:

### Claim 35 (depends on 23)

The polymeric scaffold of claim 23, wherein the enzymatic labile structures are liable to sulfatase and is
wherein * is the site covalently attached to G1, ** is the site covalently attached to D, each of R12 and R13 is independently hydrogen, an aliphatic, heteroaliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

### Claim 36 (depends on 35)

The polymeric scaffold of claim 35, wherein G1 is
wherein R7 is selected from hydrogen, an aliphatic, heteroaliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

### Claim 37 (depends on 35)

The polymeric scaffold of claim 35, wherein G1 is
wherein * is the site covalently attached to Lp, R7 is alkyl.

### Claim 38 (depends on 37)

The polymeric scaffold of claim 37, wherein -G1-Lp-D is:

### Claim 39 (depends on 1)

The polymeric scaffold of claim 1, wherein
n is an integer from 1 to 100;
m is an integer from 1 to 100; and
p is an integer from 1 to 50.

### Claim 40 (depends on 1)

The polymeric scaffold of claim 1, wherein the therapeutic agent has antiproliferative activity against a target cell or pathway.

### Claim 41 (depends on 40)

The polymeric scaffold of claim 40, wherein the antiproliferative activity is selected from cytostatic and/or cytotoxic activity.

### Claim 42 (depends on 1)

The polymeric scaffold of claim 1, wherein the therapeutic agent is selected from anti-cancer substances, cytotoxic drugs, radionuclides, vitamins, anti-AIDS substances, antibiotics, immunosuppressants, immunomodulatory compounds, therapeutic RNAs, anti-viral substances, enzyme inhibitors, neurotoxins, opioids, hypnotics, anti-histamines, tranquilizers, anti-convulsants, muscle relaxants and anti-Parkinson substances, anti-spasmodics and muscle contractants including channel blockers, miotics and anti-cholinergics, anti-glaucoma compounds, anti-parasite and/or anti-protozoal compounds, modulators of cell-extracellular matrix interactions including cell growth inhibitors and anti-adhesion molecules, vasodilating agents, inhibitors of DNA, RNA or protein synthesis, anti-hypertensives, analgesics, anti-pyretics, steroidal and non-steroidal anti-inflammatory agents, anti-angiogenic factors, antisecretory factors, anticoagulants and/or antithrombotic agents, local anesthetics, ophthalmics, prostaglandins, anti-depressants, anti-psychotic substances, anti-emetics, imaging agents.

### Claim 43 (depends on 1)

The polymeric scaffold of claim 1, wherein the therapeutic agent comprises amino acid-based molecules.

### Claim 44 (depends on 43)

The polymeric scaffold of claim 43, wherein the amino acid-based molecules comprise peptides, polypeptides, enzymes, antibodies, immunoglobulins, or functional fragments thereof.

### Claim 45 (depends on 1)

The polymeric scaffold of claim 1, wherein the therapeutic agent has a chemically reactive group.

### Claim 46 (depends on 45)

The polymeric scaffold of claim 45, wherein the chemically reactive group comprises —COOH, primary amine, secondary amine-NHR, —OH, —SH, —C(O)H, C(O)R14, —C(O)NHR15, C(S)OH, —S(O)2OR15, —P(O)2OR15, —CN, —NC or —ONO, in which R14 is selected from an aliphatic, heteroahphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, and R15 is selected from a hydrogen, aliphatic, heteroaliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

### Claim 47 (depends on 1)

The polymeric scaffold of claim 1, wherein G2 is selected from the group consisting of:
wherein each R16 is independently hydrogen, an aliphatic, heteroaliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

### Claim 48 (depends on 1)

The polymeric scaffold of claim 1, wherein G2 is

### Claim 49

A polymeric scaffold of Formula (II):
wherein,
the polymeric scaffold comprises linear polyglycerol;
L is a linking moiety comprising a functional group Wp that is capable of forming a covalent bond with the targeting moiety;
Ma is a stretcher connecting L to —NH— moiety;
each G2 is independently a functional group capable of converting into a charged state;
each G3 independently comprises a functional group capable of reacting with a reactive group in a drug release mechanism to connect the drug release mechanism to the linear polyglycerol;
n is an integer from 0 to 1000;
m is an integer from 0 to 1000;
p is an integer from 0 to 1000; and
q is an integer from 0 to 1000.

### Claim 50 (depends on 49)

The polymeric scaffold of claim 49, wherein
n is 2;
m is 2; and
p is 2.

### Claim 51 (depends on 49)

The polymeric scaffold of claim 49, wherein q is an integer from 3 to 5.

### Claim 52 (depends on 49)

The polymeric scaffold of claim 49, wherein G2 and G3 are independently selected from the group insisting of:
in which, each R17 is independently selected from a direct bond, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.

### Claim 53 (depends on 49)

The polymeric scaffold of claim 49, having a structure of Formula (IIa) or (IIb):

### Claim 54 (depends on 52)

The polymeric scaffold of claim 52, having a structure of Formula (IIc) or (IId):
wherein,
the polymeric scaffold comprises linear polyglycerol;
each G2 is independently a functional group capable of converting into a charged state;
each G3 independently comprises a functional group capable of reacting with a reactive group in a drug release mechanism to connect the drug release mechanism to the linear polyglycerol;
n is an integer from 0 to 1000;
m is an integer from 0 to 1000;
p is an integer from 0 to 1000; and
q is an integer from 0 to 1000.

### Claim 56 (depends on 55)

The polymeric scaffold of claim 55, wherein
n is 2;
m is 2; and
p is 2.

### Claim 57 (depends on 55)

The polymeric scaffold of claim 55, wherein q is an integer from 3 to 5.

### Claim 58 (depends on 55)

The polymeric scaffold of claim 55, wherein G2 and G3 are independently selected from the group insisting of:
in which, each R17 is independently selected from a direct bond, alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.

### Claim 59 (depends on 55)

The polymeric scaffold of claim 55, having a structure of Formula (IIIa) or (IIIb):

### Claim 60 (depends on 58)

The polymeric scaffold of claim 58, having a structure of Formula (IIIc) or (IIId)

### Claim 61 (depends on 55)

The polymeric scaffold of claim 55, having a weight average molecular weight Mw of 1-100000.

### Claim 62 (depends on 55)

The polymeric scaffold of claim 55, having a weight average molecular weight Mw of 10000-15000.

### Claim 63 (depends on 55)

The polymeric scaffold of claim 55, having a weight average molecular weight Mw of 5000-10000.

### Claim 64 (depends on 55)

The polymeric scaffold of claim 55, having a PDI of less than 1.5.

### Claim 65

A polymeric scaffold of Formula (IV):
wherein,
the polymeric scaffold comprises linear polyglycerol;
each La is independently a divalent moiety connecting the targeting moiety to Ma;
each Ma is independently a stretcher connecting La to —NH— moiety;
each G1 is independently a functional group connecting Lp to the linear polyglycerol;
each Lp is independently a drug release mechanism between a fragment of a therapeutic agent D and G1;
each D is independently a fragment of a therapeutic agent;
each G2 is independently a functional group capable of converting into a charged state;
n is an integer from 0 to 1000;
m is an integer from 0 to 1000;
p is an integer from 0 to 1000;
q is an integer from 0 to 1000; and
s is an integer from 1 to 8.

### Claim 66 (depends on 65)

The polymeric scaffold of claim 65, wherein the targeting moiety is an antibody and/or fragment thereof.

### Claim 67 (depends on 65)

The polymeric scaffold of claim 65, wherein the targeting moiety is an antibody IgG1, IgG2, IgG3, and IgG4.

### Claim 68 (depends on 65)

The polymeric scaffold of claim 65, wherein the targeting moiety is selected from the group consisting of a Fab, a Fab′, a F(ab′)2, a Fd, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a bispecific dsFv (dsFv-dsFv′), a disulfide stabilized diabody (ds diabody), a single-chain antibody molecule (scFv), an scFv dimer, a multispecific antibody, a camelized single domain antibody, a nanobody, a domain antibody, or a bivalent domain antibody.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 65, 66, 67, 68)

A pharmaceutical composition comprising one or more of the polymeric scaffold according to any one of claims 1-48 and 65-68 and an acceptable carrier.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 65, 66, 67, 68, 69)

A method of treating a disorder in a subject in need thereof, the method comprising administering to the subject a therapeutic effective amount of the polymeric scaffold according to any one of claims 1-48 and 65-68 or the pharmaceutical composition according to claim 69.
